The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: An intravital microscopy study in mice |
| |
| Authors: | Frank Michael Klenke Martha-Maria Gebhard Volker Ewerbeck Amir Abdollahi Peter E Huber and Axel Sckell |
| |
| Institution: | (1) Department of Orthopedic Surgery, Inselspital, University of Bern, CH-3010 Bern, Switzerland;(2) Department of Experimental Surgery, University of Heidelberg, INF 365, D-69120 Heidelberg, Germany;(3) Department of Orthopaedic Surgery, University of Heidelberg, Schlierbacher Landstrasse 200a, D-69118 Heidelberg, Germany;(4) German Cancer Research Center, INF 280, D-69120 Heidelberg, Germany;(5) Department of Trauma and Reconstructive Surgery, Charit? – Campus Benjamin Franklin, Hindenburgdamm 30, D-12200 Berlin, Germany |
| |
| Abstract: | Background The inhibition of angiogenesis is a promising strategy for the treatment of malignant primary and secondary tumors in addition
to established therapies such as surgery, chemotherapy, and radiation. There is strong experimental evidence in primary tumors
that Cyclooxygenase-2 (Cox-2) inhibition is a potent mechanism to reduce angiogenesis. For bone metastases which occur in
up to 85% of the most frequent malignant primary tumors, the effects of Cox-2 inhibition on angiogenesis and tumor growth
remain still unclear. Therefore, the aim of this study was to investigate the effects of Celecoxib, a selective Cox-2 inhibitor,
on angiogenesis, microcirculation and growth of secondary bone tumors. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
